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Abstract 
Recent research shows proper performance of self-care regimens helps postpone 
development, slow progression , and alleviate symptoms of the many complications of 
diabetes mellitus. The Transtheoretical Model (TTM) is a systematic approach to the 
acquisition of health behaviors , showing remarkable success across a wide range of 
behaviors . 
A total of 2056 participants with Insulin Dependent Diabetes Mellitus and Non-
Insulin Dependent Diabetes Mellitus were proactively recruited, and assessed regarding 
their typical performance of glucose testing and medication adherence . The two 
constructs of the TTM that were investigated were Stage of Change and Decisional 
Balance . For both behaviors , measure development followed the same procedure. When 
a Principal Component Analysis requesting two factors resulted in all decisional balance 
items loading on their theoretically appropriate constructs , the theoretical two-factor 
correlated structure was imposed on an exploratory sample . The fit indices for this model 
were excellent and the proposed model explained significantly more than even the next 
best alternative model. This model was then imposed on a confirmatory sample and a 
series of subsamples, and, again, fared quite well . 
With high proportions of participants in the Action and Maintenance stages of both 
behaviors , participants were reassigned to stage. Similarity of the single- and four-item 
algorithms shows the algorithms are internally consistent , while the cross validations by 
related variables provide external validity. Two-way Multivariate Anayses of Variance 
were performed on decisional balance for both behaviors, one by stage and gender , and 
the other by stage and type of diabetes . For glucose testing , neither interaction was 
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significant, but all three of the main effects were . For medication, neither the interaction 
of stage by gender nor the main effect for gender were significant, however , the main 
effect for stage and the interaction of stage by type were . 
As can be seen, staging and decisional balance constructs of the TTM hold up in 
one area of chronic disease behavior management--diabetes self-management. Before 
developing interventions, however , measures for the other constructs of the TTM need to 
be developed . This study is only the first of many steps needed to develop an effective, 
efficient intervention . 
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Prevalence and Incidence of Diabetes 
Diabetes mellitus is a heterogeneous family of chronic systemic diseases whose one 
common feature is the body's inability to properly metabolize sugar. This inability is the 
result of the decreased secretion or activity of insulin. Its statistics are staggering . 
Diabetes is the third leading cause of death by disease in the United States , preceded only 
by heart disease and cancer (Cox , Gonder-Frederick, Pohl , & Pennebaker , 1986; 
Ignatavicius & Bayne, 1991 ), and it is the leading cause of blindness, lower extremity 
amputations , and kidney transplants in the United States (Cox & Gonder-Frederick , 
1992) . According to the American Diabetes Association (ADA, 1993), approximately 5% 
of Western populations are affected with diabetes , which means that there is an estimated 
total of 13 million Americans who have diabetes--over half of whom are not even aware 
that they have the disease . Annually, more than 650 ,000 people are diagnosed with 
diabetes , and more than 150,000 people die from it. Its treatment costs over $90 billion 
per year in both direct costs (such as payment for health care services rendered) and 
indirect costs (such as decreased productivity and disability) . 
Furthermore , the prevalence , incidence, and mortality rates of diabetes reflect a 
bias towards older people, women , and minorities. Both incidence (number of new cases 
each year) and overall prevalence (total number of current cases) increases with age across 
races , but minorities are consistently higher . For example , prevalence increases with age 
until finally, in the 65-74 year old age bracket , it reaches 17% of whites , 26% of African-
Americans , and 33% of Hispanics . Although incidence is decreasing for women and 
increasing for men, it is still higher among women (ADA, 1993). 
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The two most common types of diabetes mellitus are insulin dependent diabetes 
mellitus (IDDM) or Type I diabetes and non-insulin dependent diabetes mellitus (NIDDM) 
or Type II diabetes . IDDM is usually diagnosed early in life--before age 30, but primarily 
during childhood--and people with IDDM need exogenous insulin to survive . NIDDM is 
usually diagnosed later in life--after age 30--and people with NIDDM have a much more 
varied regimen . Some people with NIDDM can use just diet and exercise to control their 
glucose levels, others use hypoglycemic oral medication , and others need exogenous 
insulin. 
Sometimes NIDDM can start , and continue undiagnosed for quite a while. 
Unfortunately , undiagnosed NIDDM is not a benign condition . According to Harris et al. 
(Harris , Klein, Welborne, & Knuiman, 1992), untreated hyperglycemia is a major risk 
factor for retinopathy , renal impairment , and sensory neuropathy . These complications 
both begin and progress prior to the diagnosis of NIDDM . Among newly diagnosed 
NIDDM patients, macrovascular complications are two to three times more common than 
in people with normal glucose tolerance (Harris, et al., 1992). In general , people with 
diabetes are two to four times more likely to die from cardiovascular disease and are at 
least four times more likely to have peripheral vascular disease than people without 
diabetes (ADA, 1993). 
Comorbidities and Predictors of Onset 
Family history of diabetes , obesity, poor dietary intake, lack .of exercise , high 
glucose levels, and even low education levels, low income, and urbanization (which 
usually is associated with changes in diet, physical exercise , and socioeconomic status ) all 
predict the development of diabetes (ADA, 1993; Zinman, 1984; Zinman & Vranic , 1985). 
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Estimates of the percentage of all people with diabetes who have NIDDM vary between 
80% and 95%, of which 60% to 90% are obese (Cox & Gonder-Frederick , 1992; 
Hampson, Glasgow , & Toobert, 1990). In addition to predicting the onset of diabetes , 
obesity is also associated with insulin resistance, and exacerbates the risk of cardiovascular 
disease (Abrams , Steinberg, Follick, & Raciti , 1986). 
Complications 
As was previously stated, the degree of complications and the rate at which they 
develop are related to control of glucose levels (DCCT , 1993; Ignatavicius & Bayne , 
1991 ). Unfortunately , even with strict adherence to medication , glucose testing , diet, and 
exercise behaviors , glucose levels still fluctuate excessively , and complications eventually 
arise (Cox & Gonder-Frederick, 1992). Complications include : retinopathy, neuropathy , 
nephropathy, and both peripheral (micro-) and coronary (macro-) vascular disease (both of 
which occur at accelerated rates; Cox & Gonder-Frederick , 1992; Ignatavicius & Bayne , 
1991; Rossini , Mordes, & Like, 1985) . Onset of these complications is not usually 
predictable , but some of them can be treated (Knuiman , Welborne , McCann , Stanton , & 
Constable, 1986). Many studies have been conducted in order to find correlates of 
diabetic complications . The results of these studies indicate both good and bad news . 
The good news is that some of the correlates can be controlled . For instance , the 
Diabetes Control and Complications Trial (DCCT, 1993) followed 1441 patients for an 
average of 6. 5 years . After. being randomly assigned to either the intensive (i.e., frequent 
testing of blood glucose, adjusting insulin doses according to glucose levels, more 
frequent contact with physicians) or conventional treatment regimens , the results showed 
that those in the more intensive treatment regimen had a lower cumulative incidence of all 
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of these complications than those in the conventional regimen . This was a phenomenal 
finding. Although for many years this was thought to be true , the DCCT was the first 
experimental trial to show it. Some of these group differences , however, did not appear 
until rather late in the study (i.e ., after three to five years of treatment) and even then, they 
only appeared after strict adherence to the regimen for this lengthy period of time . 
Furthermore , as may be indicated by their adherence levels alone, this study was 
composed of a very specialized sample of people with diabetes , thus its generalizability 
may be quite limited. Generalizability issues not withstanding, the potential control of and 
reduction in complications via behavioral change opens up a whole new arena for 
psychological interventions in the medical world . 
The bad news regarding complication correlates is that some of them cannot be 
controlled . For instance, using both IDDM and NIDDM patients, Knuiman et al. (1986) 
found that age, duration of diabetes, and age at diagnosis are the best time-related 
correlates of diabetic complications . Interestingly , neither complication occurrence rates 
nor risk-factor profiles differed between IDDM and NIDDM patients , suggesting that 
interventions (such as those used in the DCCT) may be able to be applied across different 
types of diabetes . 
Diabetes Self-Management Behaviors 
Upon diagnosis , people with diabetes must make major life-style changes (Curry , 
Kristal , & Bowen, 1993; Hampson, et al., 1990). These changes include the peiformance 
of many self-care behaviors , which puts a tremendous burden on the patient (Cox , et al., 
1986; Surwit , Fenglos , & Scovern , 1983). Regimen behaviors include the administration 
of medication , testing and recording of blood or urine glucose levels, modification of 
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dietary intake, adoption of physical activity, performance of routine foot care procedures. 
management of weight , attendance of regular eye examinations, reduction of stress. and 
cessation of smoking habits (Clark & Abrams , 1993; Cox & Gonder-Frederick, 1992; 
Curry , 1993; Galvotti & Fava, 1993; Heiby, Gafarian , & McCann, 1989) . Obviously , 
these behaviors make the treatment of diabetes very complex and intense (Hampson, et al., 
1990) . The behaviors themselves are extensive, continuous , tedious , expensive, and 
(sometimes) even aversive (Cox , et al., 1986) . The daily performance of these behaviors 
is no small task and is particularly difficult to do on a regular basis . 
Medication. Insulin plays a crucial role in the body's ability to metabolize glucose , 
free fatty acids, and amino acids . Perhaps most importantly, insulin enables cells to absorb 
glucose, which is a major source of energy (Ignatavicius & Bayne, 1991). Using 
medication, inadequate amounts of insulin can be compensated for in two different ways . 
First , insulin can be injected into one's body , which, as was previously stated, is the 
method the IDDM patients must use, and the method that some NIDDM patients use . 
Second, oral hypoglycemic medications can be taken , which stimulate one's pancreas to 
produce more insulin of its own and decrease insulin resistance , which is the method that 
other NIDDM patients use . 
Of all people who have diabetes, there are 27% who use insulin, 35% who use oral 
diabetes medications, 14% who use only diet, and, disturbingly , there are actually 24% 
who use none of these .therapies. These types of therapy vary by age,. with the younger 
and middle-aged age groups being more likely to use insulin, and the older age groups 
being more likely to use oral agents and diets. In addition , these treatments also vary by 
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race, with insulin being used more frequently among African-Americans , and Hispanics 
being the most likely to be untreated , (ADA, 1993). 
Without adequate amounts of insulin, the level of glucose in the blood rises above 
the target range . High levels of glucose in the blood is known as hyperglycemia . 
Conversely , with excessive amounts of insulin, the level of glucose in the blood falls below 
the target range . Low levels of glucose in the blood is known as hypoglycemia . In both 
cases , side effects can range from quite mild ones, such as headaches and irritability, to 
ones as severe as coma and even death (lgnatav icius & Bayne , 1991). 
Adherence rates for long-term treatment regimens in general are quite poor--
between 41 % and 69% with a mean of 54% (Sacket & Snow, 1979). Granted that there 
are problems with defining "adherence " and that there are likely to be differences in 
adherence rates between problem areas (as a function of regimen complexity, patient 
population , etc.) , even so, these rates are quite discouraging. Fortunately, adherence rates 
for diabetes treatment regimens tend to be better (Glasgow, McCaul , & Schafer , 1987; 
Glasgow, Toobert , Hampson , Brown , Dewinsohn , & Donnel y, 1992) . For example , 
according to Glasgow et al., (I 987) , among people with IDDM , 92% have never missed 
an injection , and 77% take their injections within 30 minutes of the prescribed time or 
activity. 
Glucose testing. Glucose self-monitoring (using either blood or urine) is an 
important diabetes self-management behavior because it enables the patients to keep their 
glucose levels within their target ranges , and to prevent episodes of hypo- or 
hyperglycemia . We know from the DCCT (1993) , that tighter control of glucose levels 
(medicating and testing more frequentl y, and following a diet and an exercise plan) 
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reduces both the incidence and the progression of the complications associated with 
diabetes. However , it is not the performance of glucose monitoring , in and of itself, that 
leads to better diabetes self-management (Baumann & Dougherty, 1988). Glucose 
monitoring simply leads to the ability to better control one's glucose levels. It is how one 
utilizes the glucose monitoring information to control glucose levels that leads to better 
diabetes self-management, which is the key to delaying the onset of complications 
(Ignatavicius & Bayne , 1991). 
Estimates of the percentage of people who test their blood glucose at least once a 
day vary from 33% to 50% (ADA, l 993 ; Ignatavicius & Bayne , l 991) . Broken down by 
type of diabetes : 79% of IDDM patients test their glucose at least once a day, 53% of 
insulin-using NIDDM patients test their glucose at least once a day, and 24% of non-
insulin using NIDDM patients test their glucose at least once a day (Ignatavicius & Bayne, 
1991). 
When looking at the performance of any testing at all over the course of a week , 
the percentages are relatively high. They range from 83% to 88% (Gonder-Frederick, 
Jullian, Cox , Clark, & Carter, 1988; Hirsch, Matthews, Rawlings, Breyfogle , Simonds, & 
Kossoyu, 1983; Wing, Epstein, Nowalk, Scott, & Koeske, 1985) . However, this is the 
percentage of people who are measuring their glucose levels at all and is NOT to be 
interpreted as being the percentage of people who test their glucose levels with the same 
frequency as they were instructed by their physician. Moreover , these. frequencies were 
based on self-reported data, which is known to overestimate actual frequencies (self-
report or subject-response bias; Wing, et al., 1985). When measuring the percentage of 
people who are performing glucose testing with the same frequency as they were 
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instructed by their physician, studies report adherence rates of 32% to 68% (Gonder-
Frederick , et al., 1988; Wing, et al., 1985). These frequencies include both self-reported 
and marked item studies. 
Factors Affecting Diabetes Self-Management 
Treatment and disease variables. Adherence to medical regimens rs a very 
complex phenomenon . It is a function of many factors and, as such, is not easily 
predicted . Some treatment related factors that impede adherence to diabetic regimens 
include behavioral restriction (i.e ., lifestyle change) , length of treatment durations (i.e ., 
one's entire remaining lifetime), frequency of behavior performance (i.e., up to several 
times daily), and delayed effects of non-adherence (i.e., up to several years later ; 
Rainwater , 1983) . Adherence also reportedly varies with the degree to which normal 
functioning is interrupted , and the degree to which the doctor and the patient agree on the 
prescribed regimen (Eckerling & Kohrs, 1984). 
Sociodemographic variables. Perhaps as may be expected , people who have more 
years of education adhere more closely to their prescribed regimens than people with 
fewer years of education (Polly, 1992) . Interestingly, however , women have a higher 
knowledge about diabetes than men (McCaul , Glasgow , & Schafer , 1987) , while men 
have a higher overall adherence than women (Littlefield , Daneman , Craven , Murry , Rodin , 
& Rydall, 1992) . 
Intrapersonal variables. Adherence to prescribed regimen behaviors reportedly 
varies with such cognitive variables as perceived health , perceived barriers, and self-
efficacy (Irvine , 1989; Kavanagh , Gooley , & Wilson, 1993; Littlefield , et al., 1992; 
Padgett , 1991; Polly, 1992) . Littlefield , et al. (1992) found that low self-esteem , low self-
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efficacy, high depression, and high rates of binge eating behavior were all associated with 
lower adherence . The same relationship between self-efficacy and adherence was found 
by Padgett ( 1991) and was found specific to glucose testing and medication adherence by 
McCaul et al. (1987) . However , neither a high correlation nor a low correlation is 
consistently found between personality variables and adherence to medical regimens , 
therefore , personality variables cannot be said to either be related or not be related to 
adherence to medical regimens (Cox & Gonder-Frederick, 1992; Cox , et al., 1986). 
Furthermore , there seem to be some very interesting relationships between the 
attitudes and beliefs of people with diabetes and their regimens (Irvine , 1989). People 
who accept their diabetes (and, therefore , are less anxious about it) may obtain better 
control by adhering more closely to their prescribed regimens (Cox , et al., 1986). In 
addition , people on insulin-dependent regimens report less positive attitudes towards 
living with diabetes than those patients on diet-only regimens , and lower levels of 
perceived health than those patients on oral medication regimens . Thus , perceived health 
seems to correlate with adherence to multiple behaviors . Those patients who are on 
insulin-dependent regimens seem to have poor attitudes about living with diabetes and 
poor perceived health . Consequently , those patients who are on insulin-dependent 
regimens may be at particularly high risk for complications due to non-adherence . 
The Transtheoretical Model of Behavior Change 
As is evident , the day to day life of people with diabetes differs .dramatically from 
that of people without diabetes . Numerous cognitive and behavioral changes are 
necessary for the successful management of diabetes and for the prevention of its 
complications . Adherence to medication regimens, regular testing of blood glucose levels, 
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modification of diet, and participation m regular physical activity or exercise are 
consistently cited as the most important behavioral changes in the self-care of people with 
diabetes (Cox & Gonder-Frederick , 1992; Heiby, et al., 1989; Rainwater, 1983). As 
things stand , " ... levels of self-care [are] inadequate for the maintenance of adequate 
metabolic control and the prevention of long term complications " (Irvine , 1989, p.10) . It 
is hypothesized , however, that by implementing disease prevention and health promotion 
strategies, we can eliminate more than 50% of its disabling complications (Sulivan, 1991 ). 
According to Kumanyika & Ewart (Kumanyika & Ewart , 1990), model based 
strategies of behavioral change may be underutilized in the diabetes population . Thus , 
there is a pressing need for the development and application of theoretical models , 
measures , and methods of health behavior change in people with diabetes . 
Systematic strategies for behavioral change can only be developed on the basis of 
corresponding models of behavior change . One of the most promising models of health 
behavior change is the Transtheoretical Model (TTM ; DiClemente & Prochaska , 1982; 
Prochaska & DiClemente , 1983; Prochaska & DiClemente , 1992) . Over its 15 years of 
theoretical and research development , common principles of change have been found that 
can account for how people succeed and fail in their attempts to modify problem 
behaviors . The TTM describes relationships among several concepts . 
Stages. The Stages of Change describe a developmental sequence of motivational 
readiness to modify problem behaviors . This sequence is composed of five stages through 
which people pass (Prochaska , DiClemente , & Norcross , 1992a) . Precontemplation (PC) 
is when a person has no intention to change in the foreseeable future (usually defined as: 
the next six months) . Contemplation (C) is when someone is seriously considering 
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changing in the foreseeable future. Preparation (P) involves two components : intention to 
change and a behavioral attempt to change. The time-frame for intention to change is 
within the next month, and the behavioral attempt to change must be in the recent past. 
Action (A) is when a person has been performing the new behavior for less than six 
months . Finally, Maintenance (M) is when a person has maintained the new behavior for 
six months or more . Movement through the stages is rarely linear (Prochaska & 
Goldstein, 1991; Prochaska , Rossi, & Wilcox, 1991; Prochaska , Velicer, Guadagnoli , 
Rossi , & DiClemente , 1991) . People often relapse , recycling back to an earlier stage of 
change. In fact , successful behavior change may require several attempts before long-term 
maintenance is achieved (Prochaska, et al., 1992a ; Prochaska, DiClemente , & Norcross, 
1992b) . 
Processes . The strategies for progressing through the Stages of Change are ten 
processes of change . The processes of change are different strategies that people use in 
their attempts to change. Each of the processes tends to be used more or less, depending 
upon one's stage of change. Successful change is characterized by a specific pattern of 
process use (DiClemente, Prochaska, Fairhurst, Velicer , Velasquez , & Rossi , 1991; 
Prochaska & Di Clemente , 1983 ). The processes can be viewed as belonging to one of 
two categories: experiential or behavioral (Kristeller , Rossi , Ockene , Goldberg , & 
Prochaska , 1992; Prochaska , Velicer , DiClemente, & Fava , 1988 ; Rossi , 1992). 
Experiential processes tend to be used more in the earlier Stages of Change. These 
processes include : consciousness raising, dramatic relief , social liberation , environmental 
reevaluation, and self-reevaluation. Behavioral processes tend to be used more in the later 
Stages of Change . These processes include : reinforcement management , stimulus control, 
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counter conditioning, helping relationships , and self-liberation (Prochaska & Goldstein, 
1991 ). 
Decisional balance. One intervening variable is decisional balance . Decisional 
balance involves the weighing of the pros and cons of changing one's behavior . Originally, 
decisional balance items were created based on Janis & Mann's decision making model 
(Janis & Mann, 1977) , which is a conflict model. It asserts that all relevant considerations 
can be sorted into eight main categories: utilitarian gains or losses for oneself, utilitarian 
gains or losses for significant others , self-approval or self-disapproval , and approval or 
disapproval from significant others . However , principal components analysis consistently 
indicates that these items are best summarized by two scales: the pros of changing and the 
cons of changing (Velicer, DiClemente , Prochaska , & Brandenburg, 1985) . 
Across many behaviors , the pros of changing have regularly been found to increase 
across the Stages of Change; while the cons of changing decrease across the Stages of 
Change, thus it has been termed the cross-over pattern of Decisional Balance (Prochaska 
& Goldstein, 1991; Prochaska , Velicer , Rossi , Goldstein , Marcus , Rakowski , et al., 1994) . 
In addition , it has been found to take one full standard deviation of change on the pros 
(i.e ., increase) , while it only takes one half of a standard deviation of change on the cons 
(i.e. , decrease) in order to move from Precontemplation to Action (Prochaska, 1994) . 
These are the "strong " and "weak " principles of change , respectively . 
Se!f-efficacy. Another intervening variable in the TIM model is Self-Efficacy . 
Bandura (1977) originall y formulated the concept of self-efficacy, positing that a person ' s 
perceived ability to perform a behavior is highly related to his/her actual ability to perform 
that behavior. In fact , self-efficac y and future performance have been found to be more 
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closely related than past behavior and future performance (Bandura, Adams, Hardy , & 
Howells , 1980; DiClemente , 1981 ). Self-efficacy can be evaluated across various 
situations in which maintaining new behaviors may be difficult. In the TTM , these 
situations are typically characterized as being individual, social, and physiological in 
nature , and are called negative/affective , positive/social , and habit/addictive , respectively 
(Velicer, DiClemente , Rossi, & Prochaska, 1990). In addition to evaluating the 
temptation to no longer perform new, healthy behaviors, confidence to continue 
performing new healthy behaviors may also be evaluated in those same situations (V elicer, 
et al., 1990) . These two subscales (Tempting Situations and Confidence) compose the 
Self-Efficacy construct of the TTM model. 
As with the pros and cons of the decisional balance construct , the temptations and 
confidence of the self-efficacy construct also show the cross-over pattern across the 
Stages of Change . Using cross-sectional data , as stage increases, temptation decreases , 
while confidence increases , both in a linear fashion (Prochaska , et al., 1991 ) . 
Application and success. Across several problem areas , these variables have 
consistently outperformed demographic and personal history variables in their ability to 
predict both successful change and relapse (Di Clemente, et al., 1991; Marcus , Rossi, 
Selby, Niaura , & Abrams , 1992b; Prochaska & DiClemente , 1985; Prochaska, et al., 
1992a; Prochaska & Goldstein , 1991; Redding , 1993; Wilcox, Prochaska , Velicer, & 
Di Clemente , 1985). As outlined by Prochaska et al. ( 1994), the TTM has been 
successfully applied across a broad range of problem behaviors . The Stages of Change 
and Decisional Balance constructs of the TTM were supported in twelve separate studies , 
on twelve different problem behaviors (Prochaska , et al., 1994). These problem behaviors 
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were : smoking (Velicer, et al., 1985); quitting cocaine (Rosenbloom , 1991); weight 
control (O'Connell & Velicer , 1988); high fat diets (Rossi , 1993) ; adolescent delinquent 
behaviors (Fiore-Lerner, 1990); safer sex (Redding , Rossi , Velicer , & Prochaska , 1989) ; 
condom use (Prochaska , Harlow , Redding , Snow, Rossi , Velicer , et al., 1992); sun 
exposure (Rossi & Blais, 1991 ); radon exposure (Rossi , 1990); sedentary lifestyles 
(Marcus , Rakowski , & Rossi , 1992a); mammography screening (Rakowski , Dube , 
Marcus , Prochaska , Velicer , & Abrams, 1992); and physicians' preventive practices with 
smoking (Eaton , Goldstein , Guadagnoli , Niaura , McDonald , & Dube , 1992) . Given the 
tremendous need for behavioral change in people with diabetes , the need for model based 
research on behavioral change, and the broad range of behaviors with which the TTM of 
behavior change has been successful , diabetes seems to be a natural target for its 
application . In fact , this need has been recognized by the diabetes professional 
community , and a special issue of Diabetes Spectrum was devoted to its application 
(Ruggiero & Prochaska, 1993) . 
Method 
Participants 
The project was part of a larger study (Ruggiero , Dryfoos , Prochaska , Rossi, 
Rossi, Greene , et al., 1996), which was done in collaboration with Johnson & Johnson . 
Participants with IDDM as well as those with NIDDM were recruited , and assessed 
regarding their typical performance of many behaviors , the two currently of interest being 
self-monitoring of glucose level and medication adherence . The recruited sample 
consisted of 2800 people with diabetes , 1300 of whom were representative of the U.S. 
diabetes population , as well as an additional 1500 insulin-using participants , who were 
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included in order to increase our sample of Type I participants (in particular) . Due to the 
low expected response rate of approximately 58%, a post-card prompt was planned , 
however , the actual response rate was 73 .4% resulting in a total of 2056 participants , 
hence, the post-card prompt was not executed . There were roughly equal numbers of 
participants obtained from the representative (n=988) and augmented (n= 1068) samples ; 
the distribution of type of diabetes among each subsample varied accordingly (see Table 
1 ) . 
The sample was an older one (M=5 9. 1, SD= 14 .1) with many retired people 
(43 .9%) . Most were females (61.8%) , married (62 .0%), and fairly well educated (46.8% 
had at least some college) . While the sample was largely Caucasian (69 .9%) there was an 
unusually high representation of Native Americans (23 .0%; see Table 2). 
Type of diabetes will be broken down into Type I (those diagnosed below age 30 
and have taken insulin since diagnosis) , Type II using insulin (those diagnosed at or above 
age 30 and are currently using insulin), and Type II not using insulin (those diagnosed at 
or above age 30, are not currently using insulin but may or may not be taking pills). 
Participants with type I diabetes constituted 13.8% of the sample, participants with type II 
diabetes who were using insulin constituted 55.9% of the sample, and participants with 
type II diabetes who were not using insulin constituted 30.2% of the sample. There was 
8.8% of the sample who who could not be typed (10.4% of the representative sample and 
7.3% of the augmented sample). Less than 20% of the sample had heard of the DCCI 
and were aware of its results . When looked at by type of diabetes , it was a disappointing 
number of those with type I diabetes (3 5. 7%) who were aware of the DCCI results . The 
percentages , however , were in the expected direction, with less of those with type II 
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diabetes using insulin who were aware of the results ( 19. 9% ), and even fewer of those 
with type II diabetes not using insulin who were aware of the results (10.6% ; see Table 2) . 
The distribution of staging for all behaviors was severely skewed , with the vast 
majority of participants indicating they were in Maintenance (based on the one-item 
algorithms , the range was from 73.4% to 94.7%; see Table 3) . Regarding general health 
status , overall , the sample was in relatively good health . When looking at potential 
complications of diabetes, both individually and using a composite variable, the majority of 
participants do not have problems : over 50% of the participants answer "no" to each listed 
complication, and the mean number of complications ( out of a total of 16) was 3. 8 
(SD=2 . 7). As far as hospital and emergency room admissions , routine office visits, and 
days of work missed due to diabetes problems , all of these were severely skewed and 
kurtotic. Only 10.4% of the sample had been admitted to the hospital within the last year , 
of those admitted the mean number of admissions was 2.2 (SD=5 .6), and the mode and 
median were only I. The mean length of stay for these admissions was 10.4 days 
(SD=13 .2), however , the mode was only 3 days and the median was 6 days. There were 
14.3% of the participants who had emergency visits, among whom the mean number of 
visits was 2.6 (SD=3 . l) , the mode was I visit, and the median was 2 visits . Almost 90% 
of the participants visited their doctors for routine exams within the last year, the mean 
was semi-annually (M=S.8 , SD=7.0), but both the mode and median were quarterly (4 
times in the last year) . Finally of those who were employed part- or full-time, 16.4% 
missed any work at all, the mean indicated that when they missed any they missed quite a 
bit, (M=9.3, SD=20 .5), but the mode was only 2 days and the median was 3 days (see 
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Table 4) . For frequencies of health status variables specific to each behavior (such as 
recommended regimens, skipping, behavior in the last week , etc.), see Tables 5-7. 
Using listwise deletion, there were 1186 participants with complete decisional 
balance data for all glucose testing items (number of items=26), and 1573 participants 
with complete decisional balance data for all medication items (number of items=l8) . 
When considering those who have complete decisional balance data for the final measures 
(number of items=l2) and who also have stage for these behaviors, there are 1282 
participants for glucose testing and 1495 participants for medication . 
Measures 
Typical demographic items were collected along with some descriptive diabetes 
characteristics (both general and behavior-specific). 
Staging. Two different methods were used in this study to assess stage of change 
for adherence to both self-monitoring of glucose testing and medication regimens. 
Adherence to medication regimens was broken down into adherence to pill regimens and 
adherence to insulin regimens. First, there was a series of four dichotomous items. 
Second, there was a single item with five stage-appropriate alternatives . 
Decisional balance. Decisional balance items measure the importance of each 
opinion (item) to the participants in their decision to perform each behavior. Items were 
rated on a five-point Likert scale, where 1 = "Not At All Important " and 5 = "Extremely 
Important ." Thus, lower scale scores indicate little importance of .that scale to the 
participants' decision making process and higher scale scores indicate more importance of 
that scale. There are 26 decisional balance items for glucose testing, 14 are pros and 12 
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are cons . There are 18 decisional balance items for medication , nine are pros , and nine are 
cons . 
Procedure 
Items were generated , randomized , given to confederates who were 
knowledgeable about the TTM model , and these people were asked to sort the items into 
the categories they believed the items represented. Any ambiguous items, such as those 
items that multiple confederates sort into incorrect categories , were then discarded. 
Items , sorted incorrectly by only one person , or sorted correctly but were difficult to 
understand , were then edited . Some new items were then created. 
Participants were proactively recruited by mailing them packages including both a 
letter about the study and the study questionnaire . There was only one point of contact 
for each subject , after which the subject's participation in this study was complete . As 
incentives for completing the questionnaire , there were 16 drawings for cash prizes--three 
drawings for prizes of $150 each, five drawings for prizes of $100 each, and eight 
drawings for prizes of $50 each. 
The measure development process included a senes of Principal Components 
Analyses (PCA) and Confirmatory Factor Analyses (CF A). First , a PCA was performed 
on an exploratory sample and the number of components to be retained was determined 
using both Velicer ' s (Velicer , 1976) Minimum Average Partial correlation (MAP) 
procedure, and Horn ' s (Horn, 1965) Parallel Analysis (PA) procedure , both of which have 
been well supported in the literature (Zwick & V elicer, 1986) . No items were deleted 
based solely on the PCA. Next , several CF As were performed on the exploratory sample. 
in order to determine which model best fit the data . Then, the best model was applied 
19 
(using CF A) to the second half of the sample--the confirmatory half Last of all, this 
model was applied to various sub-samples ( using CF A) as validation for the measure ' s 
application to these sub-samples . 
Crosstabs of the two staging algorithms for each of the three behaviors indicated 
how well they matched (i.e., to what extent they indicated the same stages for the same 
people) . Crosstabs of stage with related variables , for example, how many times 
participants skipped each behavior , provided some validity for staging . 
Next , Discriminant Functions Analyses (DFAs) were done in order to determine 
how well stage could be predicted from decisional balance . Finally, Multivariate Analyses 
of Variance (MANOVAs) were done in order to determine whether or not there were 
differences across the stages on decisional balance ; univariate Analyses of Variance 
(ANOVAs) and Tukey tests were used as follow-up tests to the MANOVAs . 
Except for the PCAs, which were done using Component Analysis Extended 
(CAX; Velicer, Fava, Zwick , & Harrop , 1988), all statistics were done using SPSS , 
version 4. 0 ( 1990); the CF As used the LISREL program , version 7 .16; the crosstabs used 
the CROSST AB program; the DF As used the DISCRIMINANT program ; the 
MANOV As used the MANOV A program ; and the ANOV As used the ONEW A Y 
program with the subcommand TUKEY to obtain the Tukey tests . 
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Results 
Glucose Testing 
The sample of 1186 participants with complete glucose testing decisional balance 
data was randomly split into exploratory and confirmatory subsamples of n=579 and 
n=607, respectively . 
Glucose Testing Decisional Balance Measure Development 
Principal Components Analysis (PCA). Using the exploratory subsample and 
listwise deletion, a 26x26 matrix of interitem correlations was created (n=579) . PCA was 
then conducted using CAX . MAP suggested a four component solution ( accounting for 
60. 1 % of the variance), while PA suggested a three component solution ( accounting for 
5 6. 1 % of the variance). The third component , suggested by both MAP and PA, was 
composed of three items that seemed to be related to one ' s health care provider. The 
fourth component, suggested by MAP , was composed of only two items that were both 
related to exercise . The requested two factor solution resulted in all items loading on their 
theoretically appropriate constructs , most items loaded well ( .554-.876 and .381-.726) , 
and this solution accounted for 49.4% of the variance. Using an oblique rotation , the two 
factors had a correlation of .119. 
Confirmatory Factor Analyses (CFA): The Two Factor Correlated Model. Given 
that the requested two-factor PCA solution resulted in all of the items loading 
appropriately, an attempt was made to impose the theoretical two..,factor correlated 
structure on the exploratory sample. Several iterations of models were performed, deleting 
items at each step with any of the following characteristics: loading less than .50 on their 
appropriate factor , loading .30 or higher on both factors , or items that had extremely high 
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modification indices. The final measure consisted of six Pros of glucose testing and six 
Cons of glucose testing. The fit indices for this model were : 1) x\ s3)=157 .57, J2 <.001; 2) 
Goodness of Fit Index= .958; and 3) Root Mean Square Residual=.056. The glucose 
testing Pros factor consisted of items that loaded from .68 to .87, and its internal 
consistency rating (coefficient alpha) was .91. The Glucose testing Cons factor consisted 
of items that loaded from .52 to .80, and it had a coefficient alpha of .81. The correlation 
of the Pros and Cons of glucose testing was -0.128, see Tables 8 and 9, and Figure 1. 
Comparison models. In order to test one ' s choice of a model, one should test 
several plausible alternative models , this way, either a better fitting model will be found or 
the model of interest will be confirmed . Two of the alternative models chosen are used as 
baselines. These are the null model and the random two factor correlated model. The null 
model forces each item to act as a factor , none of which are allowed to be related to any 
others . The random two factor correlated model forces random items to be assigned to 
each of two factors that are allowed to correlate . The other two alternative models were 
plausible models. One was a one factor model, which asserts that all items are part of one 
construct. Some items may be on one end of the construct and other items may be on the 
other end, but they are all part of one construct. The other model was a two factor 
uncorrelated model, which asserts that the items represent two unrelated constructs . The 
results of the alternative models are also presented in Tables 8 and 9. 
First , was the null model. Its fit indices were : 1) x2c66l=2998.30, Q <.001 ; 2) 
Goodness of Fit Index=.435; and 3) Root Mean Square Residual=.316 ; but , by definition, 
the factor loadings and coefficient alphas cannot be computed . Second , was the two factor 
random model. It did not converge , hence , there are no fit indices, factor loadings, or 
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coefficient alphas to report . Third, was the one factor model. Its fit indices were : 1) 
x2cs4i=l067 .24, 12 <.001; 2) Goodness of Fit Index= .683; and 3) Root Mean Square 
Residual=.183 . The single factor consisted of items that loaded from -.20 to . 88; its 
coefficient alpha was .76. Last , was the two factor uncorrelated model. Its fit indices 
were : 1) x2(s4)=164 .71, 12 <.001; 2) Goodness of Fit Index= .956 ; and 3) Root Mean 
Square Residual= .065 . The glucose testing Pros factor consisted of items that loaded 
from .68 to .87, and the glucose testing Cons factor consisted of items that loaded from 
.52 to .80. The coefficient alphas for the Pros and Cons of glucose testing in this model 
are, by definition, the same as for the two factor correlated model (Pros alpha= . 9 I , Cons 
alpha=.81) . 
Chi-square difference tests were performed in order to test whether or not 
significant differences existed between the proposed theoretical model and each of the 
alternative models . These results are presented in Table 10. The proposed model (the 
two factor correlated model) explained significantly more than even the next best 
alternative model (the two factor uncorrelated model) . 
Since both the null model and the one factor model, as evidenced by their fit 
indices, were such poor models, they were both enormously different from the two factor 
correlated model. The random model was so poor that it could not even be compared 
(because it did not converge) . The differences between the two facto r uncorrelated model 
and the two factor correlated model are minimal, however , the correlated model does fit 
better (has a lower x2 and RMSR, and has a higher GFI) . Therefore , while the differences 
between the fit indices of the two best models were slight, the two factor correlated model 
does explain the data best (fits the data significantly better than the uncorrelated model) . 
,.. 
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Cross validation. Using the confirmatory subsample (n=607) , the two factor 
correlated model still fared quite well. Its fit indices were : 1) x\ s4)=227 .73, Q <.001 ; 
2) Goodness of Fit Index= .941; and 3) Root Mean Square Residual=.057 . The glucose 
testing Pros factor consisted of items that loaded from . 71 to . 83, and its coefficient alpha 
was .89. The glucose testing Cons factor consisted of items that loaded from .53 to .77, 
and its coefficient alpha was .81 (see Tables 8 and 9). The correlation of the Pros and the 
Cons of glucose testing was -0.092 (see Figure 2). 
Applicability of final model to sub-populations. In order to determine the 
applicability of this new measure to different subsamples of people with diabetes , the 
whole data set was broken down into three subsamples : 1) people with type I diabetes 
(n=202) , 2) people with type II diabetes who are on insulin (n=723) , and 3) people with 
type II diabetes who are not on insulin (n=l 89) . Next, these subgroups were combined 
into: all insulin users (n=925), and all participants with Type II diabetes (n=9 l 2). Finally, 
the model was tested on the entire sample (n=l 186). 
For participants with Type I diabetes , the fit indices were : 1) x\s3>=131.90 , 
g<.001; 2) Goodness of Fit Index=. 904; and 3) Root Mean Square Residual= . 078. The 
glucose testing Pros factor consisted of items that loaded from . 68 to . 86, and its 
coefficient alpha was . 91. The glucose testing Cons factor consisted of items that loaded 
from .51 to .84, and its coefficient alpha was .81. For the Type II subsample using insulin, 
the fit indices were : 1) x2cs3>=224 .91, g<.001; 2) Goodness of Fit Index= .950; and 3) Root 
Mean Square Residual= .057. The glucose testing Pros factor consisted of items that 
loaded from .69 to .87, and its coefficient alpha was .90 . The glucose testing Cons factor 
consisted of items that loaded from . 5 5 to . 7 4, and its coefficient alpha was . 81. For the 
I 
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Type II subsample not using insulin, the fit indices were : 1) x\s3i=l42 .27, g<.001; 2) 
Goodness of Fit Index=.893 ; and 3) Root Mean Square Residual= .075. The glucose 
testing Pros factor consisted of items that loaded from .68 to .84, and its coefficient alpha 
was .89. The glucose testing Cons factor consisted of items that loaded from .31 to .90, 
and its coefficient alpha was . 73. 
For the subsample of insulin users, the fit indices were: 1) X2cs3i=271.81 , g<.001; 
2) Goodness of Fit Index= .953; and 3) Root Mean Square Residual= .056 . The glucose 
testing Pros factor consisted of items that loaded from .69 to .85, and its coefficient alpha 
was . 90. The glucose testing Cons factor consisted of items that loaded from . 5 5 to . 77, 
and its coefficient alpha was . 81. For the subsample of all Type II participants , the fit 
indices were : 1) x\ 53i=291.52 , g<.001; 2) Goodness ofFit Index= .949; and 3) Root Mean 
Square Residual= .055. The glucose testing Pros factor consisted of items that loaded 
from .70 to .87, and its coefficient alpha was .90. The glucose testing Cons factor 
consisted of items that loaded from .52 to .76, and its coefficient alpha was .80. For the 
whole sample, the fit indices were : 1) X2<53i=340 .89, g<.001; 2) Goodness of Fit 
lndex=.954 ; and 3) Root Mean Square Residual= .054. The glucose testing Pros factor 
consisted of items that loaded from . 69 to . 86, and its coefficient alpha was . 90. The 
glucose testing Cons factor consisted of items that loaded from . 53 to . 79, and its 
coefficient alpha was . 81. These results are presented in Tables 11 and 12. 
Staging Algorithms 
Given the high proportion of participants in the Action and Maintenance stages 
(already presented in Table 3), an attempt was made to validate this by using other 
behavioral indicators . Consequently , some participants were removed from the Action 
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and Maintenance stages based on their reported and recomended testing frequencies. If 
participants were testing as often as they were told by their physicians to test , they were 
kept in Action and Maintenance ; if they were testing less often, they were put in the 
"Don't Know Standard " (or DK) group (see Table 13). 
Using this new staging method , a crosstab of the single- and four-item staging 
algorithms for glucose testing adherence was performed. The two overlapped (indicated 
the same stage) for 89.4% of the participants . Allowing a one-stage margin-of-error in 
each direction , the two algorithms were off for 4.8% of the participants. Furthermore , 
when looking at the crosstabs for each staging algorithm by number of times in the past 
year participants have skipped testing their glucose levels, the anticipated pattern 
emerged--as people progressed through the stages, they skipped their glucose testing less. 
This pattern was true for both the single-item and the four-item staging algorithms , and 
the two were almost exactly the same. Since the two algorithms are so similar, and since 
more data is lost as the number of items increases , logic would suggest using the most 
parsimonious algorithm--the one-item algorithm. 
Predicting Stage from Decisional Balance : Discriminant Function Analysis (DF A) 
A Discriminant Function Analyses (DF A) was performed to predict in what stage 
the DK group would best belong in a five stage model. The DF A used the two decisional 
balance variables (the Pros and Cons of glucose testing) as predictors of membership in 
one categorical dependent variable (the five stages of change for glucose testing) . Of the 
original 1573 participants with decisional balance or staging for glucose testing , 1250 had 
both , and were testing their blood (those testing only their urine were excluded) . The 
DF A left the DK stage as "ungrouped " cases and only the "grouped " cases (the first five 
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stages) are used for the actual analysis; those results, were used to classify the 
"ungrouped " cases into one of the five stages . Therefore, while the analyses predicted 
group membership for the 220 participants in the DK group , the analysis was based on 
only the 1030 participants who are in PC, C, P, A, or M . 
Two discriminant functions were derived , both functions were significant 
predictors of stage . Function one had a Wilks' ').., = .622, Q<.001, and accounted for 
35 .32% of the total variance, function two had a Wilks' ').., = .962, Q<.001, and accounted 
for 3. 82% of the total variance . The first function separates all five of the stages , then the 
second function separates the "stable" stages (PC and M) from the "unstable " stages (C, 
P, and A). Classifying the DK group , 9.5% were placed in PC, 12.7% were placed in C, 
18.6% were placed in P, 21.4% were placed in A, and 37 .7% were placed in M (see Table 
14). 
Stage Differences on Decisional Balance : Multivariate Analysis of Variance (MANO VA) 
Decisional balance by stage and gender. In order to determine whether or not 
men and women differed across the stages of change on decisional balance, a 5x2 
between-subjects MANOV A was performed . The two independent variables were 
glucose testing stage (PC, C, P, A, and M) and gender (male and female) . The dependent 
variables (DVs) were the Pros and Cons of glucose testing and they were entered at the 
same time . Those in the DK group and those who tested their glucose only by urine were 
excluded . There were 1028 participants included in the analysis . 
Using the Wilks ' criterion , the combined DVs were not significantly affected by 
the interaction of stage and gender , Ecs. 2034)=1.422 , Q>.05 , but were significantly affected 
independently by both stage , Ecs. 20341=66 .393, Q<.001 and gender , Ec2. !017)=6.089 , Q<.01. 
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The effect of stage was very strong (r/=.207) , however, the effect of gender was very 
weak (ri 2=.0l 1). 
Since the interaction of stage and gender in the MANOV A was not significant, no 
two-way follow-up ANOV As were done , however , each of the significant one-wa y 
MANOV As (stage and gender) were followed up with one-way ANOV As . 
Looking at stage of change for glucose testing, the ANOV A for the Pros of 
glucose testing was significant , E<4. 1018)=88 .792 , 12<.00l , as was the ANOVA for the Cons 
of glucose testing , E<4. 1018)=4 7 .241 , 12<.001. The effect size of the Pros was very strong 
(ri 2= .259) and the effect size of the Cons was moderate (ri 2= .157) . See Table 15 for 
means and standard deviations of the glucose testing Pros and Cons by stage of change for 
glucose testing . See Figure 3 for the pattern of glucose testing Pros and Cons across the 
Stages of Change for glucose testing. 
Following the ANOVAs, Tukey Pairwise-Comparisons were used to determine 
which stages were significantly different from one another. Regarding the Pros of glucose 
testing, those in Precontemplation were different from everyone ; Contemplation and 
Preparation did not differ from each other , but both of them differed from Action and 
Maintenance . As for the later stages, those in Action and Maintenance differed from those 
in the early stages (PC , C, and P) , and those in Action were different from those in 
Maintenance (see Table 15) . 
Regarding the Cons of glucose testing , those in Precontemplation , Contemplation, 
and Preparation did not differ from one another, but all of them differed from those in 
Maintenance ; Contemplation and Preparation also differed from those in Action . As for 
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the later stages, those in Action differed from those m Maintenance ; and those m 
Maintenance differed from everyone (see Table 15). 
Looking at gender , the ANOV A for the Pros of glucose testing was significant, 
Ec1. 1018>=8 .642, 12<.Ol, as was the ANOVA for the Cons of glucose testing, Eo. 10181=4.453 , 
12<.05. The effect sizes of both the Pros and the Cons were small (Pros : ri 2=.OO8, Cons : 
ri 2=.OO4). See Table 15 for means and standard deviations of the glucose testing Pros and 
Cons by gender. See Figure 4 for the pattern of glucose testing Pros and Cons across 
gender. No Tukey tests were needed for the Cons of glucose testing by gender , because 
there were only two groups (male and female). 
Decisional balance by stage and type of diabetes. Because there were very few 
Type I people in the Action stage of glucose testing , the two stages of Action and 
Maintenance were collapsed. Therefore, a 4x3 between-subjects MANOV A was 
performed on two dependent variables, which were the Pros and Cons of glucose testing . 
The two independent variables were glucose testing stage (PC, C, P, and AIM) and type 
of diabetes (type I, type II using insulin, and type II not using insulin). 
Using the Wilks' criterion, the combined DVs were not significantly affected by 
the interaction of stage and type, t.(12. 1904)= 1.688, 12>.05, but were significantly affected 
independently both by stage, Ec6. 1904)=63 .138, Q<.001, and by type , Ec4. 19o41=3 .O57, Q<.05 . 
The effect size of stage on the DV s was strong ( ri 2= . l 66), but the effect size of type on 
the DVs was very weak (ri 2=.OO6). For a summary of all the MANOV As (see Table 15). 
Since the interaction of stage of change and type of diabetes in the MANOV A was 
not significant, no two-way ANOV As were done. The significant one-way MANOV As 
were followed up with one-way ANOV As. The ANOV As on stage will not be reported 
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again for either the Pros or the Cons of glucose testing, since they were already reported 
above . Looking at type of diabetes, the ANOV A on the Pros of glucose testing was not 
significant, Ec2• 953i=0 .021, p_>.05. The ANOVA on the Cons of glucose testing was 
significant, Ec2• 953>=6 . l 15, p_<.01, but with a small effect size (r/= .013). See Table 15 for 
means and standard deviations of the glucose testing Pros and Cons by type of diabetes . 
See Figure 5 for the pattern of glucose testing Pros and Cons across type of diabetes . 
The follow-up Tukey Pairwise-Comparison test showed that on the Cons of 
glucose testing , the participants with type I diabetes were significantly different from type 
II participants who were on insulin, but not from type II particiapants who were not on 
insulin. The two categories of type II participants , however , were not different from one 
another. 
Medication 
The sample of 1573 subjects with complete medication decisional balance data was 
randomly split into exploratory and confirmatory subsamples of n=784 and n=789 , 
respectively. 
Medication Decisional Balance Measure Development 
Principal Components Analys is (PCA). Using the exploratory subsample (n=784), 
a PCA was conducted on the l 8x 18 matrix of interitem correlations . MAP suggested a 
two component solution with all items loading on their theoreticall y appropriate constructs 
(.468- .782 and .588 to .732), accounting for 46 .2% of the variance .. Using an oblique 
rotation , the two factors had a correlation of .070. PA suggested a four component 
solution ( accounting for 59. 5% of the variance). The third component , suggested by PA, 
was composed of four con items that were mostly related to taking medication . One of 
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these items was complex, and loaded poorly on the two constructs on which it did load . 
The fourth component , suggested by PA, was composed of three pro items and one con 
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item most of which were related to satisfaction . Two of these items were complex and 
both of them loaded poorly on the constructs on which they did load. Hence , the third 
and fourth factors were fairly weak. 
Confirmatory Factor Analysis (CFA): Two Factor Correlated Model. Given that 
the requested two-factor PCA solution resulted in all of the items loading on their 
theoretically appropriate constructs , an attempt was made to impose the theoretical , two-
factor correlated structure using the exploratory sample. After several iterations of 
models, deleting items at each step that loaded less than .50 on their appropriate factor , 
items that loaded .30 or higher on both factors, and items that had extremely high 
modification indices, the final measure consisted of six Pros of medication and six Cons of 
medication . The fit indices for this model were: 1) X2cs3)=202 .51, 12<.001 ; 2) Goodness of 
Fit Index= .959; and 3) Root Mean Square Residual=.040. The Pros factor consisted of 
items that loaded from .67 to .81, and its internal consistency rating (coefficient alpha) 
was .86. The Cons factor consisted of items that loaded from .51 to .78, and it had a 
coefficient alpha of .81. The correlation of the Pros of medication adherence and the Cons 
of medication adherence was -0.089 (see Tables 16 and 17 and Figure 6). 
Comparison models. As was previously stated , in order to test one ' s choice of a 
model, one should test several plausible alternative models. The same . set of alternative 
models were tested with the medication decisional balance, because the same theory was 
being tested . The results to the alternative models are presented in Tables 16 and 17. 
I 
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First, was the null model. Its fit indices were : 1) x2<66J=3340 .34, Q<.001 ; 2) 
Goodness of Fit Index=.472 ; and 3) Root Mean Square Residual= .294; but , by definition, 
the factor loadings and coefficient alphas cannot be computed . Second , was the two factor 
random model. Its fit indices were : 1) x2<s3J=1490 .30, 12<.00l ; 2) Goodness of Fit 
Index=.677 ; and 3) Root Mean Square Residual=.186 . The first factor consisted of items 
that loaded from -0 .13 to .82, and its coefficient alpha was .55. The second factor 
consisted of items that loaded from -0.10 to .74, and its coefficient alpha was also .55. 
Third, was the one factor model. Its fit indices were : 1) x2(54J= 1499 .48, 12<.001 ; 2) 
Goodness of Fit Index= .676; and 3) Root Mean Square Residual= .186. The single factor 
consisted of items that loaded from -.132 to .81; its coefficient alpha was . 74. Finally, was 
the two factor uncorrelated model. Its fit indices were : 1) x\s4J=206 .99, 12<.00l; 2) 
Goodness of Fit lndex= .958; and 3) Root Mean Square Residual= .048 . The Pros factor 
consisted of items that loaded from . 67 to . 82, and its coefficient alpha, by definition, was 
the same as for the two factor correlated model (.86) . The Cons factor consisted of items 
that loaded from . 51 to . 78, and its coefficient alpha was also the same as for the two 
factor correlated model (.81 ). 
Chi-square difference tests were performed in order to test whether or not 
significant differences existed between the proposed theoretical model and each of the 
alternative models . These results are presented in Table 18. The theoretical model (the 
two factor correlated model) explained significantly more than even the next best 
alternative model (the two factor uncorrelated model) . 
As can be seen, the differences between the null model, the one factor model, and 
the random model each compared to the two factor correlated model were all enormous . 
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These three comparison models, as expected and as evidenced by their fit indices, were all 
poor models . However , the differences between the two factor uncorrelated model and the 
two factor correlated model are minimal. The correlated model does do better (has a 
lower x2 and RMSR and a higher CFI) . Therefore, as with the glucose testing decisional 
balance, while the differences between the fit indices of the two best models were slight, 
the two factor correlated model seems to explain the data best. 
Cross validation. Using the confirmatory subsample (n=789) , the two factor 
correlated model still fared quite well . The fit indices were : 1) x\ s3)=201.24 , p<.001 ; 2) 
Goodness of Fit Index= .957; and 3) Root Mean Square Residual= .046 . The Pros factor 
consisted of items that loaded from .64 to .81, and its coefficient alpha was .83. The Cons 
factor consisted of items that loaded from .52 to .77, and its coefficient alpha was .82. 
The correlation of the Pros and the Cons of medication adherence was -0. 003 ( see Figure 
7). 
Applicability of final model to sub-populations. In order to determine the 
applicability of this new measure to different subsamples of people with diabetes , the data 
was broken down into three subsamples : 1) people with type I diabetes (n=234 ); 2) people 
with type II diabetes who are on insulin (n=855) ; and 3) people with type II diabetes who 
are not on insulin (n=388) . Finally, the model was tested on the entire sample (n=l573) . 
For the Type I subsample, the fit indices were : 1) x2<s3>=118 .87, p<.001; 2) 
Goodness of Fit Index= .920 ; and 3) Root Mean Square Residual= .052 : The Pros factor 
consisted of items that loaded from .63 to .86, and its coefficient alpha was .88. The Cons 
factor consisted of items that loaded from . 52 to . 72, and its coefficient alpha was . 79. For 
the Type II subsample using insulin, the fit indices were : 1) X2<53>=196.30, p<.001; 2) 
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Goodness of Fit Index= .962; and 3) Root Mean Square Residual=.046. The Pros factor 
consisted of items that loaded from .61 to .81, and its coefficient alpha was .84. The Cons 
factor consisted of items that loaded from .52 to .74, and its coefficient alpha was .82. For 
the Type II subsample not using insulin, the fit indices were: 1) X2cs3)=123 .10, 12<.00l ; 2) 
Goodness of Fit Index=.948 ; and 3) Root Mean Square Residual=.050. The Pros factor 
consisted of items that loaded from .64 to .79, and its coefficient alpha was .84. The Cons 
factor consisted of items that loaded from .50 to .72, and its coefficient alpha was .80. For 
the whole sample, the fit indices were: 1) x2cs3>=309 .15, Q<.001 ; 2) Goodness of Fit 
Index=.967 ; and 3) Root Mean Square Residual= .040. The Pros factor consisted of items 
that loaded from . 64 to . 81, and its coefficient alpha was . 85. The Cons factor consisted 
of items that loaded from . 52 to . 77, and its coefficient alpha was . 81. These results are 
presented in Tables 19 and 20. 
Staging Algorithms 
Insulin adherence. Given that the vast majority of subjects were in Maintenance , a 
cross-check was done to validate this . If subjects were taking at least as much insulin as 
they were supposed to be taking, they stayed in Maintenance , otherwise , they were put 
into a DK group . There were no subjects in Contemplation . Doing a crosstab of the 
single-item and four-item staging algorithms for insulin adherence , the two new algorithms 
overlapped for 98.3% of the subjects . Allowing a one-stage margin-of-error in each 
direction , the two algorithms were off for only 0.5% of the subjects . Furthermore , when 
looking at the crosstab of stage by number of times in the past year subjects have skipped 
their insulin, the anticipated pattern emerged--as people progressed through the stages , 
they skipped their insulin shots less. This pattern was true for both the single-item and the 
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four-item staging algorithms, and the two were very similar. Since the two algorithms are 
so similar, and since more data is lost as the number of items increases, logic would 
suggest using the most parsimonious algorithm--the one-item algorithm. 
Pill adherence. As with insulin, the vast majority of subjects were in Maintenance . 
So, again, a cross-check was done to validate this . If subjects were taking at least as 
much medication as they were supposed to be taking, they stayed in Maintenance, 
otherwise , they were put into a DK group. Again, there were no subjects in 
Contemplation. Doing a crosstab of the single-item and four-item staging algorithms for 
pill adherence, the two overlapped for 95.2% of the subjects . Allowing a one-stage 
margin-of-error in each direction, the two algorithms were off for only 2.5% of the 
subjects . As with insulin, when looking at the crosstab of stage by number of times in the 
past year subjects have skipped their pills, the anticipated pattern emerged--overall, as 
people progressed through the stages , they skipped their pills less. This pattern was true 
for both the single-item and the four-item staging algorithms . Since the two algorithms 
are so similar, and since more data is lost as the number of items increases , logic would 
suggest using the most parsimonious algorithm--the one-item algorithm. 
Stage Differences on Decisional Balance : Multivariate Analysis of Variance (MANOVA) 
Decisional balance by stage and gender . To determine whether or not males and 
females differed across the stages of change on decisional balance, a 4x2 between-subjects 
MANOVA was performed. The two independent variables were medication stage (PC, 
CIP, A, and M) and gender (male and female). The dependent variables were the Pros and 
Cons of medication adherence and they were entered at the same time . There were I 048 
subjects included in the analysis. 
35 
Using the Wilks' criterion , neither the interaction of stage and gender , Ec6. 
2078i=O. 764, 12>.OS, nor the main effect of gender , Ec2. 1039)=0.907, 12>.OS, were significant. 
The main effect for stage , Ec6. 2078i= 13. 806, 12<.001, was significant, however , its effect size 
was weak (r/= .O38). 
Since neither the interaction of stage and gender nor the main effect for gender 
were significant in the MANOV A, the two-way follow-up ANOV As and the one-wa y 
follow-up ANOV As for gender were not done on the Pros or the Cons of medication 
adherence . Only the significant one-way MANOV A on decisional balance by stage of 
change was followed-up by one-way ANOV As and Tukey tests on each dependent 
variable . 
The ANOVA for the medication Pros was significant, Ec3, 10401=18 .371, 12<.OOl, as 
was the ANOVA for medication Cons, E(3. 104oi=9.4O3, 12<.OOl. The effect sizes, however , 
were both weak (Pros : r{= .O5O; Cons : r{= .O26). See Table 21 for means and standard 
deviations of the medication Pros and Cons by stage of change for medication . See Figure 
8 for the pattern of the medication Pros and Cons across the stages of change for 
medication. 
Tukey Pairwise-Comparisons were used to determine which stages were 
significantly different from one another. Regarding the Pros of medication adherence , 
those in Precontemplation and the Contemplation/Preparation group were different from 
those in Action and Maintenance. Similarly, regarding the Cons of medication adherence , 
those in Precontemplation and the Contemplation/Preparation group were different from 
those in Maintenance. 
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Decisional balance by stage and type of diabetes. To determine whether or not 
people with different types of diabetes differed across the stages of change on decisional 
balance, a 4x3 between-subjects MANOVA was performed . The two independent 
variables were medication stage (PC, C/P, A, and M) and type of diabetes ( type I, type II 
using insulin, and type II not using insulin). The dependent variables were the Pros and 
Cons of medication adherence and they were entered at the same time. There were 985 
subjects included in the analysis. 
Using the Wilks ' criterion , the interaction of stage and type was significant, Ec12, 
1944 1=3 .883, p_<.001, hence, the main effects of type and stage were not investigated . The 
effect size, however , was weak (r/= .023) . 
Since the interaction of stage and type in the MANOV A was significant, two-way 
follow-up ANOV As were done on each the Pros and the Cons of medication adherence . 
The interaction of stage and type on the ANOV A for the medication Pros was significant, 
E<G. 973)=6.626, p_<.001, however, its effect size was small (ri2=.039) . The interaction of 
stage and type on the ANOVA for the medication Cons was not significant, Ec6. 973i=l .135, 
p_>.05. The significant main effect for stage was already presented above (see Table 21 
and Figure 9). Tukey Pairwise-Comparisons cannot be computed for two-way 
interactions . 
Discussion 
The first objective for each of the two behaviors was to develop decisional balance 
measures . This was accomplished by using a series of exploratory and confirmatory 
procedures to determine and verify the structure of each measure . Exploratory procedure s 
included a PCA, a series of measurement models (used to determine poor items that 
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should be deleted) , and several alternative measurement models (serving as comparisons) . 
Confirmatory procedures included verifying the selected model on the second half of the 
data, as well as applying this model to several different subsamples . Overall, it was found 
that the typical, expected two factor correlated decisional balance model fit both the 
glucose testing and the medication adherence behaviors . In addition to fitting the second 
half of the data, final model did respectably well on all the subsamples of different types of 
diabetes , and quite well on the entire sample. Once again, the decisional balance model of 
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the TTM held up . 
The second objective for each of the two behaviors was to develop staging 
measures . This was accomplished by a series of crosstabs to determine the differences 
between the two staging algorithms for each behavior and also the validity of each staging 
algorithm as reflected by several related behavioral variables . The results showed 
remarkable similarity of the single- and four-item algorithms not only when compared to 
one another, but also when each was compared to related behavioral variables. Moreover , 
the similar results of the cross validations done between each of the algorithms and across 
other related behavioral variables indicates that the algorithm does seem to be measuring 
the construct of stage , and people are consistent in their answers. Additionally , it is 
noteworthy that the percentages of people in the Action and Maintenance stages are 
consistent with adherence rates in previous diabetes self-management literature . 
Finally, group differences on decisional balance were found using MANOV As, 
looking at stage of change , gender, and type of diabetes. Regarding main effects, there 
were significant differences on decisional balance by stage of change for both of the 
investigated behaviors, all in the expected directions. These differences indicate the 
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amount of change needed to progress through the stages of change . There ware also 
significant differences on decisional balance by gender , but only on glucose testing , not on 
medication . So, men and women judge the advantages and disadvantages of glucose 
testing differently, but judge the advantages and disadvantages of medication similarly. 
Regarding type of diabetes , there was a main effect for glucose testing , but type of 
diabetes interacted with stage of change for medication ( discussed below ; this was the 
only significant interaction) . This means that people with different types of diabetes judge 
the advantages and disadvantages of glucose testing differently. 
The lack of interactions between stage and gender for both behaviors , shows that 
even though men and women weight the advantages and disadvantages of glucose testing 
differently, they change the same way across the stages of change . Similarly, the lack of 
interaction between stage and type for glucose testing , shows that people with different 
types of diabetes change the same way across the stages of change . This lack of 
interactions is a powerful statement in support of the TTM . 
On a theoretical level, the interaction between stage and type of diabetes for 
medication adherence is understandable, given that the medication regimens are so very 
different for the different types of diabetes . This interaction , however, may actually just be 
a product of the staging distribution rather than a meaningful difference between the 
groups . While the distribution of stage was skewed for both behaviors , it was 
tremendously skewed for medication adherence. This tremendous skewness produces 
unreliability in the data and it could be argued that stage of change for medication was so 
skewed that it was no longer meaningful and its results were not interpretable . Decisional 
balance scores are standardized , which is most useful among evenly distributed categorical 
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variables . Tremendous skewness leads to very heavy weighting at one end of the 
distribution, and very little weighting at the other therefore, the scores at one end of the 
distribution will be very close to the mean, and those at the other end will be very extreme . 
This skewness, however , is not likely to be due to the sampling procedures given that the 
sample was proactively recruited from a representative sample of people with diabetes and 
the response rate was so high. Since sampling does not seem to be an issue , then more 
work may need to be done to better understand the Stages of Change in the medication 
area . 
As was previously shown , diabetes has a tremendous impact, not only on patients , 
but also on the health care system and society . If the development and successful 
application of a stage-based behavior change program for the self-management of diabetes 
were to help prevent the development, slow the progression , and alleviate the symptoms 
of the many complications of diabetes , it could then in tum have a tremendous impact on 
patients , the health care system, and society . The development of these measures is one 
step in the direction of developing interventions. In order to develop interventions , 
however , measures need to be developed for the other constructs of the TTM. As 
evidenced by all of these findings, the staging and decisional balance constructs of the 
TTM can now be said to hold up outside the cancer prevention field . There is now 
promise for the application of the TTM in at least one area of chronic disease . 
-~- ----------------------,1 
Table 1 Frequencies for the Representative and Augmented Samples Across the 
Whole Sample and by Type of Diabetes 
Type of Diabetes 
Total Type I Type II , Type II, 
Sample Insulin No Insulin 
Sample N N (%) N {%) N (%) 
Representative 988 72 (8.1) 289 (32.7) 524 (59.2) 
Augmented 1068 186 (18.8) 760 (76.8) 44 (4.3) 
Total 2056 258 (12 .5) 1049 (51.0) 568 (27.6) 
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Table 2 Demographics and Key Variables/or the Whole Sample and by Type of 
Diabetes 
DEMOGRAPHICS Total Type I Type II , Type II , 
Insulin No Insulin 
N {%} N (%} N (%) N (%) 
Gender 
Ma le 784 (38.2) 107 (41. 5) 392 (37.5) 230 (40 .5) 
Female 1267 (61.8) 151 (58.5) 654 (62.5) 338 (59.5) 
Race 
Hispanic 25 (1.2) 4 (1.6) 12 (1.2) 7 ( 1.2) 
Afr ican Ame rican 107 (5.3) 7 (2.8) 59 (5 .7) 27 (4.8) 
Asian 12 (0.6) 5 (0.5) 4 (0.7) 
Native Ame rican 466 (23.0) 25 (9.8) 24 1 (23.3) 154 (27 .5) 
Caucas ian 14 14 (69.9) 2 18 (85.8) 716 (69.3) 369 (65 .8) 
Marital Status 
Marrie d 1272 (62.0) 166 (64.3) 643 (61.5) 348 (61.4) 
Sep/Di v/W id 560 (27.3) 28 (10. 9) 320 (30.6) 171 (30.2) 
Single 176 (8.6) 43 (16 .7) 74 (7.1) 38 (6 .7) 
Single, with Sig. Othe r 42 (2.0) 21 (8.1) 9 (0 .9) 10 (1.8) 
Living Arrangement 
With Partne r 1289 (62.8) 174 (67.7) 639 (6 1.0) 359 (63.3) 
With Oth ers 291 (14 .2) 44 (17.1) 156 ( 14. 9) 69 (12.2) 
Alone 464 (22.6) 39 (15.2) 245 (23.4) 138 (24 .3) 
In a Care Facili!X 9 (0.4) 8 (0.8) 1 (0.2) 
Workin g Status 
Full T ime 466 (23.3) 122 (48.0) 173 (17.0) 132 (23.8) 
Part Time 151 (7.6) 25 (9 .8) 69 (6.8) 41 (7.4) 
Unemployed 72 (3.6) 21 (8.3) 34 (3.3) 9 (1.6) 
Retired 877 (43.9) 17 (6.7) 525 (5 1.5) 272 (49 . 1) 
Homemake r 307 (15.4) 46 (18. 1) 146 (14.3) 8 1 (14 .6) 
Other 124 (6.2) 23 (9.1) 72 (7 .1) 19 (3.4) 
Education 
Some High School 325 (16.2) 21 (8.3) 177 (17 .2) 92 (16. 7) 
High School 742 (37.0) 78 (30 .8) 400 (38.8) 207 (37.6) 
Some College 538 (26.8) 74 (29 .2) 278 (27 .0) 144 (26 .1) 
College 206 (10.3) 45 (17.8) 89 (8.6) 5 1 (9.3) 
Post-Graduate 194 (9.7) 35 ( 13 .8) 86 (8 .3) 57 (10.3) 
DCCT 
Hear d of an d A ware 387 (19.3) 91 (35. 7) 206 (19 .9) 59 (10.6) 
Heard of and Not Aware 245 (12.2) 33 (12.9) 136 (13.2) 6 1 (10.9) 
Not Hear d of and Not Awa re 1377 (68.5) 131 (51.4) 692 (66. 9) 439 (78 .5) 
T~'l>e 
Type I 258 (13 .8) 258 (100 .0) 
Type II, on insulin 1049 (55 . 9) 1049 (100 .0) 
Type II, not on insulin 568 (30.2) 568 (100 .0) 
M (SD) M (SD) M (SD) M (SD) 
Age 59 .1 (14. 1) 39 .7 (11.1) 62.8 (10 .8) 62.3 ( 12.2) 
Age at Dia2J)osis 45.8 (17.2) 15.8 (7.6) 49.9 (1 1.4) 54.5 (11.5) 
BMI 30. l (8.1) 25 .9 (6.1) 30.9 (8 .1) 30.8 (8.3) 
42 
Table 3 Stage Distributions Using the One-Item Algorithm for All Three Behaviors 
Prior to Re-Staging Across the Whole Sample and by Type of Diabetes 
STAGES OF CHANGE Total Type I Type II , Type II , 
Insulin No Insulin 
N % N % N % N % 
Glucose Testing Stage 
Precontemplation 73 (4.6) 19 (8.0) 33 (3.6) 16 (5.1) 
Contempl ation 69 (4.4) 11 (4.6) 38 (4.2) 12 (3.8) 
Preparation 130 (8.3) 20 (8.4) 59 (6.5) 37 (11.8) 
Action 146 (9.3) 15 (6.3) 69 (7.6) 51 (16.3) 
Maintenance 1156 (73.4) 172 (72.6) 710 (78.1) 197 (62.9) 
Total 1574 258 909 313 
Medicat ion Stage- Overall 
Precontemplation 24 (1.3) 3 (l.2) 9 (0.9) 7 ( 1.5) 
Contemplation 4 (0.2) 2 (0.8) 1 (0.1) I (0.2) 
Preparati on 17 (0.9) 1 (0.4) 5 (0.5) 10 (2.1) 
Action 77 (4.1) 3 (1.2) 45 (4.3) 22 (4.7) 
Main tenance 1755 (93.5) 247 (96.5) 976 (94.2) 427 (91.4) 
Total 1877 256 1036 467 
Medication Stage- Insulin 
Precontemplation 14 (1.0) 3 (1.2) 9 (0.9) 
Contemplat ion 3 (0.2) 2 (0.8) (0.1) 
Preparation 6 (0.4) (0.4) 5 (0.5) 
Action 50 (3.7) 3 (1.2) 45 (4.4) 
Maintenance 1296 (94.7) 247 (96.5) 973 (94.2) 
Total 1369 256 1033 
Medication Stage-- Pills 
Precontemplation 29 (4.0) 18 (9.4) 7 (1.5) 
Contemplation 2 (0.3) 1 (0.5) 1 (0.2) 
Preparation 12 (1.7) (0.5) 10 (2.1) 
Action 44 (6.1) 15 (7.9) 22 (4.7) 
Maintenance 631 (87.9) 156 (81.7) 427 (91.4) 
Total 718 191 467 
Table 4 General Health Status Variables Across the Whole Sample and by Typ e of 
Diabetes 
HEALTH STATUS: Total Type I Type II, Type II , 
General Insulin No Insulin 
N (%) N (%) N (%) N (%) 
Eye problems (retinopath y) 
Yes 618 (30. 1) 122 (47.3) 350 (33.4) 99 (17.4) 
No 1438 (69. 9) 136 (52. 7) 699 (66.6) 469 (82.6) 
Kidney problem s (nephrop athy) 
Yes 240 (11. 7) 48 (18.6) 139 (13 .3) 35 (6.2) 
No 1816 (88.3) 210 (8 1.4) 910 (86.7) 533 (93.8) 
Decrease or loss of feelin g in legs or feet (neuropathy) 
Yes 736 (35.8) 95 (36 .8) 460 (43.9) 125 (22 .0) 
No 1320 (64.2) 163 (63.2) 589 (56. 1) 443 (78.0) 
Foot problems (ulcers , infections , sores) 
Yes 339 (16.5) 45 (17.4) 200 (19. 1) 65 (1 1.4) 
No 17 17 (83.5) 213 (82.6) 849 (80.9) 503 (88.6) 
Sexual problems 
Yes 451 (2 1. 9) 49 (19.0) 268 (25.5) 107 (18.8) 
No 1605 (78.1) 209 (81.0) 781 (74.5) 46 1 (8 1.2) 
High Blood Pres sure (hyperten sion) 
Yes 991 (48.2) 70 (29. l ) 553 (52.7) 30 1 (53.0) 
No 1065 (51.8) 188 (72.9) 496 (47.3) 267 (47.0) 
Angina 
Yes 341 (16.6) 28 (10.9) 229 (21.8) 59 (10.4) 
No 1715 (83.4) 230 (89.1) 820 (78 .2) 509 (89.6) 
Congestive Heart Disease 
Yes 278 (13 .5) 14 (5.4) 197 (18.8) 47 (8.3) 
No 1778 (86.5) 244 (94.6) 852 (81.2) 521 (91.7) 
Heart Attack 
Yes 266 (12.9) 17 (6.6) 179 (17. 1) 52 (9.2) 
No 1790 (87. 1) 241 (93.4) 870 (82.9) 516 (90.8) 
Stroke 
Yes 150 (7.3) 14 (5.4) 96 (9.2) 30 (5.3) 
No 1906 (92.7) 244 (94.6) 953 (90.8) 538 (94.7) 
M (SD) M (SD) M (SD} M (SD) 
# Comelic ations 3.8 (2.7) 3.4 (2.8) 4.4 (2.7) 3.3 (2.2) 
# Hoseit al admissions {year) 0.2 (2.0) 0.3 (0.9) 0.3 (2.7) 0.0 (0.3) 
# Days in the hosp. (all adms) 10.4 (13.2) 12.2 (18.4) 9.9 (11.8) 12.7 (13.5) 
# ER admissions {year} 0.9 (14.5) 2.6 (31.3) 0.4 ( 1.6) 0. 1 (0.7) 
# Routine doctor 's visits (vear) 5.3 (6.9) 5.4 (7.8) 5.9 (7.3) 4.3 (5.3) 
# Days of work missed h•ea r) 1.5 (8.9) 2.0 (9.3) 2.3 (12.2) 0.4 (1.9) 
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Table 5 Health Status Variables Specific to Glucose Testing Across the Whole Sample 
and by Type of Diabetes 
HEALTH STATUS: Total Type I Type II , Type II , 
Glucose Testing Insulin No Insulin 
N (%) N (%) N (%) N (%) 
Told to test glucose 
Yes 1647 (81.0) 245 (95.3) 966 (92 .4) 313 (55.6) 
No 386 (19.0) 12 (4.7) 80 (7.6) 250 ( 44.4) 
How do you test your glucose? 
Urine 49 (3.2) 3 (1.3) 17 (1.9) 24 (7.9) 
Strips 96 (6.2) 17 (7.5) 49 (5.4) 22 (7.3) 
Meter 1400 (90.6) 207 (91.2) 834 (92.7) 256 (84.8) 
# Times skipp ed for 1 day or more in the last yea r 
Never 541 (34.8) 82 (35.0) 347 (38.6) 76 (24.6) 
1-5 times 364 (23.4) 47 (20. 1) 219 (24.3) 74 (23.9) 
6-10 times 166 (10.7) 24 (10.3) 79 (8.8) 50 (16.2) 
11-20 times 143 (9.2) 17 (7.3) 80 (8.9) 35 (11.3) 
2 1 or more times 342 (22.0) 64 (27.4) 175 (19.4) 74 (23. 9) 
M (SD) M (SD) M (SD) M (SD) 
# Times told to test glucose per 
wee k 10.3 (8.4) 16.4 (10.2) 10.4 (7.8) 5.4 (5.2) 
Avg. # time s you test )!er week 9.0 (8.6) 13.7 (10.8) 9.4 (8.3) 4.6 (4.6) 
# Last seven da:ys tested 4.6 (2.6) 5.2 (2.6) 5.0 (2.5) 3.4 (2.5) 
# Tests done in the last week 8.7 (8.4) 13.4 (10.5) 9.0 (8.1) 4.5 (5.3) 
# Planned breaks in J!ast month 6.1 (7.8) 8.1 (7.9) 6.3 (8.7) 3.7 (4.4) 
# Time s skiee ed in ea st month 5.5 (10.4) 8.3 (13.2) 4.8 (9.5) 4.6 (8.0) 
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Table 6 Health Status Variables Specific to Insulin Across the Whole Sample and by 
Type of Diabetes 
HEALTH STATUS: Total T)'pe I Type II, Type II, 
Insulin Insulin No Insulin 
N (%) N (%) N {%) N (%) 
Insulin at diagnosis 
Yes 784 (39.0) 258 (100 .0) 498 (48 .5) 8 (1.4) 
No 1228 (61.0) 528 (51.5) 557 (98.6) 
Take insulin now 
Yes 1390 (67.6) 258 (100 .0) 1049 (100.0) 
No 621 (30.2) 568 (100 .0) 
How do you take your insulin? 
Pump 8 (0.6) 3 (1.2) 4 (0.4) 
Injections 1336 (99.4) 249 (98 .8) 1012 (99 .6) 
# Times skipped for 1 day or more in the last year 
Never 1126 (82.0) 223 (87.1) 838 (81.0) 
1-5 times 190 (13.8) 26 (10.2) 151 (14 .6) 
6-10 times 25 (1.8) 6 (2.3) 19 (1.8) 
11-20 times 16 (1.2) 14 (1.4) 
21 or more times 16 (1.2) (0.4) 13 (1.3) 
M (SD) M (SD) M (SD) M (SD) 
# Times told to take insulin 
per week 23.2 (58.0) 26.9 (36.9) 22.7 (64.0) 
# Insulin shots in last week 12.6 (6.1) 14.8 (7.1) 12. l (5.6) 
# Times ski1?1?ed in past month 0.6 (3.0) 0.8 (5.8) 0.5 (1.4) 
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Table 7 Health Status Variables Specific to Oral Diabetes Medication Across the 
Whole Sample and by Type of Diabetes 
HEALTH STATUS: Total Type I Type II, Type II, 
Pills Insulin No Insulin 
N (%) N (%} N (%) N {%) 
Take pills now 
Yes 828 (42.4) lO (3.9) 283 (28 .6) 479 (84.3) 
No 1126 (57.6) 245 (96 .1) 708 (71.4) 89 (15.7) 
M (SD) M (SD) M (SD) M (SD) 
# Times told to take pills per 
week 39.4 (112.8) 22.8 (33.4) 31.7 (90.9) 44 .8 (126.2) 
# Pills in the last week 13.3 (10.3) 12.8 (12.8) 12.2 (9.9) 13.8 (10 .4) 
# Times ski~~ed in ~ast month 1.2 (5.4) 0.8 (1.3) 1.0 (3.4} 1.3 (6.2) 
# Times ski~~ed in ~ast ~ear 3.3 (11.8) 1.2 (1.9) 2.9 ( 11.6) 3.4 ( 12.2) 
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Table 8 Fit Indices for Glucose Testing Decisional Balance: Exploratory CFAs Run 
on the First Half of the Sample (n=597); Confirmatory CFA Run on the Second Ha(f 
of the Sample(n=607) 
Null One Random Two Two Confirmatory 
Model Factor Two Factor Factor Sample 
Model Factor Uncorr. Correlated Two Factor 
Correlated Model Model Correlated 
Model* Model 
x2 2998 .30 1067.24 164.71 157.57 227 .73 
df 66 54 54 53 53 
.I! <.001 <.001 <.001 <.001 <.001 
GFI .435 .683 .956 .958 .941 
CFI .654 .962 .964 .940 
RMSR .316 .183 .065 .056 .057 
Alpha .7621 
Pros .9080 .9080 .8894 
Cons .8060 .8060 .8059 
*did not converge 
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Table 9 Factor Loadings for Glucose Testing Decisional Balance: Exploratory CF As 
Run on the First Half of the Sample (n=597); Confirmatory CFA Run on the Second 
Half of the Sample(n=607) 
Null One Random Two Two Confirmatory 
Model Factor Two Factor Factor Sample 
Model Factor Uncorr. Correlated Two Factor 
Correlated Model Model Correlated 
Model* Model 
Pros of Glucose Testing 
1 838 Factor 1 .837 .838 .745 
7 .822 Factor 1 .823 .823 .798 
9 .760 Factor 2 .763 .762 .723 
13 .683 Factor 1 .682 .682 .709 
21 .754 Factor 2 .755 .755 .738 
26 .875 Factor 2 .874 .874 .833 
Cons of Glucose Testing 
4 -.154 Factor 1 .725 727 .681 
8 -.197 Factor 2 .795 .800 .771 
IO -.017 Factor 1 .652 .649 .628 
12 .072 Factor 1 .610 .604 .633 
14 - .080 Factor 2 .529 .528 .592 
24 - .071 Factor 2 .521 .520 .531 
*did not converge 
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Table IO Chi-Square Difference Tests Between the Two Factor Correlated Model/or 
Glucose Testing Decisional Balance and Each Comparison Model 
Model x2 Difference df Difference I! 
Null 2840 .73 13 <.001 
One Factor 909 .67 1 <.001 
Two Factor, Uncorrelated 7.14 1 <.01 
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Table 11 Fit Indices for the Final Two Factor Co"elated Mode/for Glucose Testing 
Decisional Balance Run on the Overall Sample and then on Different Sub-Samples 
Entire Type I ss Type II ss, Type II ss, All ss All 
Sam~le on insulin no insulin on insulin Tr~e II ss 
N 1186 202 723 189 925 912 
x2 340.89 131.90 224.91 142.27 271.81 291.52 
df 53 53 53 53 53 53 
I! <.001 <.001 <.001 <.001 <.001 <.001 
GFI .954 .904 .950 .893 .953 .949 
CFI .953 .930 .953 .897 .954 .947 
RMSR .054 .078 .057 .075 .056 .055 
Alpha 
Pros .8993 .9052 .8983 .8892 .9006 .8980 
Cons .8056 .8125 .8087 .7319 .8099 .7966 
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Table 12 Factor Loadings for the Final Two Factor Correlated Model for Glucose 
Testing Decisional Balance Run on the Overall Sample and then on Different Sub-
Samples 
Entire Type I ss Type II ss, Type II ss, All ss All 
Samele on insulin no insulin on insulin T:yee II ss 
Pros of Glucose Testing 
1 .795 .803 .786 .789 .789 .792 
7 .811 .855 .787 .811 .810 .794 
9 .743 .776 .741 .735 .755 .740 
13 .694 .679 .692 .688 .688 .695 
21 .746 .776 .757 .683 .762 .743 
26 .855 .818 .868 .837 .853 .865 
Cons of Glucose Testing 
4 .703 .764 .702 .596 .718 .687 
8 .785 .843 .744 .897 .771 .762 
10 .638 .601 .660 .580 .638 .642 
12 .618 .640 .641 .407 .637 .601 
14 .560 .510 .554 .521 .549 .554 
24 .525 .511 .555 .308 .550 .521 
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Table 13 Stage Distributions Using the One-Item Algorithm for All Three Behavior s 
Across the Whole Sample and by Type of Diabetes 
Total Type I Type II , Type II , 
Insulin No Insulin 
N (%) N (%) N (%) N (%) 
Glucose Testing Stage 
Precontemplation 73 (4.9) 19 (8.4) 33 (3.8) 16 (5.6) 
Contemplation 69 (4.7) 11 (4.9) 38 (4.4) 12 (4.2) 
Preparation 130 (8.8) 20 (8.9) 59 (6.8) 37 (12. 9) 
Action 85 (5.8) 6 (2.7) 39 (4.5) 33 {l 1.5) 
Maintenance 870 (58.9) 117 (52.0) 544 (63.l ) 156 (54.4) 
Don 't Know Standard 249 (16.9) 52 (23 .1) 149 (17.3) 33 (11.5) 
Total 1404 225 862 287 
Medic ation Stage- Overall 
Precontemplation 24 (1.4) 3 (1.3) 3 (0.9) 7 (l.6) 
Contemplation 4 (0.2) 2 (0.8) (0. 1) (0.2) 
Preparati on 18 (1.0) (0.4) 6 (0.6) 10 (2.3) 
Action 54 (3. 1) l (0.4) 33 (3.5) 15 (3.4) 
Maintenance 1122 (64.8) 85 (35.4) 606 (63.7) 363 (82. 9) 
Don 't Know Standard 510 (29.4) 148 (61.7) 296 (3 1.l ) 42 (9.6) 
Total 1732 240 951 438 
Medicat ion Stage- Insulin 
Precontempl ation 14 ( l.l ) 3 (1.3) 9 (0.9) 
Contemplation 3 (0.2) 2 (0.8) (0.1) 
Preparation 6 (0.5) (0.4) 5 (0.5) 
Action 35 (2.9) (0.4) 33 (3.6) 
Maintenance 7 18 (60. 9) 85 (35.4) 59 1 (65. 9) 
Don 't Know Standard 459 (34.5) 148 (61.7) 29 1 (29.0) 
Total 1235 240 930 
Medication Stage-- Pills 
Precontemplation 29 (4.1) 18 (9.7) 7 ( 1.5) 
Contemplation 2 (0.3) (0.5) I (0.2) 
Preparati on 12 ( l. 7) (0.5) 10 (2.2) 
Action 27 (4.9) 7 (6.5) 15 (3.5) 
Maintenance 524 (78.9) 126 (71.0) 363 (83 .4) 
Don 't Know Standard 71 (10. 1) 22 ( 11.8) 42 (9.2) 
Total 665 175 438 
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Table 14 Classification Results of a DFA Run on Those Staged from PC to 
Maintenance (n=338) in order to Place Doctor's Standard Group (n=682) and Don't 
Know Standard Group (n=209) into a Four-Stage Model 
Predicted Groue Membershie 
N PC C p A M 
Glucose Testing Stage of Change 
Precont. 60 38 9 5 ,., 5 _, 
63.3% 15.0% 8.3% 5.0% 8.3% 
Cont. 60 16 21 10 11 2 
26 .7% 35.0% 16.7% 18.3% 3.3% 
Prep. 114 30 27 21 23 13 
26.3% 23 .7% 18.4% 20.2% 11.4% 
Action. 70 9 5 10 16 30 
12.9% 7.1% 14.3% 22 .9% 42.9% 
Maintenance 726 39 47 40 131 469 
5.4% 8.0% 4.3% 18.1% 64 .6% 
Don't Know 220 21 28 41 47 83 
Standard 9.5% 12.7% 18.6% 21.4% 37.7% 
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Table 15 The Pros and Cons of Glucose Testing By Stage of Glucose Testing, Gender, 
and Type of Diabetes 
Stage of Change 
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
Gender 
Male 
Female 
Type of Diabetes 
Type I 
Type II , Insulin 
Type II, No Insulin 
NS not significant 
g<.05 
g<.01 
*** g<.001 
Pros of Glucose Testing 
N M (SD) 
Fe 4. 1018)=88. 792***, 112=.259 
60 33.4 3 (12.6) 
60 43 .6b (10 .5) 
114 44 .5b ( 10.2) 
70 49 .2c (10.2) 
724 52 .9d (8.0) 
.... 2 
Fo , t018J=8.642 , 11 =.007 
408 48 .73 (11.1) 
620 51.0b (9 .7) 
Fc2,9s3J=0 .021 
162 48 .7 
606 51.1 
197 48 .2 
NS 
(11. 9) 
(9 .9) 
(10 .3) 
Cons of Glucose Testing 
N M (SD) 
••• 2 7 Fc4. 101sJ=47.241 , 11 = .15 
60 54 .53 (11.0) 
60 58.3 3 (9 .9) 
114 57 . la (8.5) 
70 51.0b (9 .3) 
724 47 .2c (9.2) 
* 2 Fo . 101sJ=4.453 , 11 = .004 
408 48.7 3 (9 .9) 
620 50 .3b (10.2) 
** 2 Fc2,953l=6 . l 15 , 11 = .013 
162 51.4 3 (10.4) 
606 49 .0bc (10 .1) 
197 49 .lac (9.1) 
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Table 16 Fit Indices for Medication Decisional Balance: Exploratory CFAs Run on 
the First Half of the Sample (n=784); Confirmatory CFA Run on the Second Half of 
the Same_le(n=789l 
Null One Random Two Two Confirmatory 
Model Factor Two Factor Factor Sample 
Model Factor Uncorr. Correlated Two Factor 
Correlated Model Model Correlated 
Model Model 
x2 3340.34 1499.48 1490.30 206 .99 202.51 154.97 
df 66 54 53 54 53 53 
I! .001 <.001 <.001 <.001 <.001 <.001 
GFI .472 .676 .677 .958 .959 .967 
CFI .559 .561 .953 .954 .967 
RMSR .294 . 186 . 186 .048 .040 .040 
Alpha .7384 
Pros .5463 .8601 .8601 .8345 
Cons .5543 .8099 .8099 .8 165 
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Table 17 Factor Loadings for Medication Decisional Balance: Exploratory CFAs Run 
on the First Half of the Sample (n=784); Confirmatory CFA Run on the Second Half 
of the Same_le(n=789l 
Null One Random Two Two Confirmatory 
Model Factor Two Factor Factor Sample 
Model Factor Uncorr. Correlated Two Factor 
Correlated Model Model Correlated 
Model Model 
Pros of Glucose Testing 
1 .704 .712 .701 .702 .638 
7 .669 .679 .670 .670 .675 
11 .679 .689 .683 .682 .668 
13 .812 .820 .815 .814 .807 
15 .722 .738 .722 .722 .729 
17 .679 .699 .677 .678 .647 
Cons of Glucose Testing 
2 -.096 -.099 .701 .702 .708 
4 .039 .045 .511 .509 .548 
6 -.132 -.131 .776 .777 .766 
8 -.068 -.087 .620 .620 .632 
10 -.067 - .058 .722 .721 .726 
12 - .095 - .097 .540 .540 .523 
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Table 18 Chi-Square Difference Tests Between the Two Factor Co"e/ated Mode/for 
Medication Decisional Balance and Each Comparison Model 
Comparison Models x2 Difference df Difference I! 
Null 3137 .83 13 <.001 
One Factor 1296.97 <.001 
Two Factor, Uncorrelated 4.48 <.05 
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Table 19 Fit Indices/or Final Two Factor Correlated Model/or Medication 
Decisional Balance Run on the Overall Same_le and then on Di(Jerent Sub-Same_les 
Entire Type I ss Type II ss, Type II All ss All Type II 
Sample on insulin ss, no on insulin 
insulin 
N 1573 234 855 388 1089 1243 
x2 309 .15 118.87 196.30 123.10 213.40 260 .82 
df 53 53 53 53 53 53 
.I! <.001 <.001 <.001 <.001 <.001 <.001 
GFI .967 .920 .962 .948 .967 .965 
CFI .959 .936 .959 .951 .964 .958 
RMSR .040 .052 .046 .050 .041 .043 
Alpha 
Pros .8479 .8796 .8430 .8375 .8531 .8421 
Cons .8138 .7896 .8212 .7998 .8146 .8158 
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Table 20 Factor Loadings for Final Two Factor Co"elated Model for Medication 
Decisional Balance Run on the Overall Same.le and then on Different Sub-SameJes 
Entire Type I ss Type II ss, Type II All ss on All Type 0 
Sample on insulin ss, no insulin ss 
insulin 
Pros of Medication 
1 .638 .692 .605 .637 .628 .620 
7 .675 .736 .643 .648 .671 .649 
11 .668 .757 .674 .637 .685 .664 
13 .807 .858 .805 .787 .821 .799 
15 .729 .774 .730 .727 .745 .724 
17 .647 .634 .667 .641 .658 .659 
Cons of Medication 
2 .708 .620 .722 .695 .707 .715 
4 .548 .621 .553 .496 .561 .539 
6 .766 .715 .791 .713 .778 .771 
8 .632 .590 .637 .653 .631 .639 
10 .726 .660 .737 .722 .721 .737 
12 .523 .520 .522 .526 .513 .519 
Table 21 The Pros and Cons of Medication By Stage of Medication , Gender, and 
Stage by Type of Diabetes 
Pros of Medication Cons of Medication 
N M {SD} N M {SD) 
Stage of Change *** 2 Fc4. 1484)=14 .165 , Tl = .037 *** 2 Fc4, 1484)=6 .993 , Tl = .019 
Precontemplation 12 33.2a (17 .8) 12 59_9a ( 13.4) 
Cont./Prep . 19 39 _7a (15 .9) 19 56 .2a ( 10.2) 
Action 51 49 . lb (8 .5) 51 52.2ab (11.0) 
Maintenance 966 50 .2b (9 .61 966 45 .5b (9 .5) 
Gender F(l. 1040)=0 .102NS Fo . 104oi= 1. 702 NS 
Male 600 48 .7 (11.1) 600 49 .3 (9 .7) 
Female 894 50 .6 {9.0) 894 50.4 {10.01 
Stage by Type of Diabetes *** 2 Fcs.1394i=4 .958 , ri = .028 Fcs.1394)=0 .984 NS 
PC/Type I 3 45 .2 (10 .6) 3 54 .1 (16 .2) 
PC/Type II , Insulin 7 33 .7 (16 .0) 7 59 .3 (12.6) 
PC/Type II, No Insulin 1 -2 .2 (0) 1 79.4 (0) 
C&P /Type I ,.., 55.4 (5 .9) 3 57.2 (8 .5) ., 
C&P/Type II , Insulin 5 45 .6 (11.8) 5 61.2 (13.2) 
C&P/Type II, No Insulin 10 30 .1 (13 .7) 10 54 .0 (9.4) 
N Type I 1 28.3 (0) I 47 .9 (0) 
NType II , Insulin 31 50 .2 (6 .8) 31 53.4 (10 .9) 
NType II , No Insulin 14 48 .3 (10 .5) 14 51.2 ( 11. 8) 
M/Type I 79 49 .5 (10 .0) 79 49.4 (8 .7) 
M/Type II , Insulin 517 51.0 (9 .3) 517 50.2 (10 . I) 
M/Type II , No Insulin 314 49 .3 (10.0) 314 48 .6 (9 .0) 
DK/Type I 134 49.6 (10 .8) 134 48 .3 (8.4) 
DK/Type II , Insulin 252 51 .0 (9.0) 252 50 .9 (10.4) 
DK/Type II , No Insulin 38 48 .2 (10 .7) 38 49 .6 (10 .5) 
NS 
not significant 
n< 05 
.. 
n<.01 
••• 
n<.001 
60 
6 1 
Figure J. Two factor correlated CFA for glucose testing decisional balance on 
exploratory sample (n=579). 
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Figure 2. Two factor correlated CF A for glucose testing decisional balance on 
confirmatory sample (n=607). 
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Figure 3. Glucose testing decisional balance by stage of change for glucose testing, 
whole sample (N=1055). 
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Figure 4. Glucose testing decisional balance by gender; whole sample (N=I055). 
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Figure 5. Glucose testing decisional balance by type of diabetes; whole sample 
(N=992). 
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Figure 6. Two factor correlated CF A for medication decisional balance on 
exploratory sample (n=784). 
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Figure 7. Two factor correlated CFA for medication decisional balance on 
confirmatory sample (n=789). 
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Figure 8. Medication decisional balance by stage of change for medication; whole 
sample (N=1048). 
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Figure 9. Medication decisional balance by stage of change for medication and type 
of diabetes; whole sample (N=985). 
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